This podcast explores the growing concern of muscle loss associated with GLP-1 receptor agonist therapy for obesity management. It highlights the need for greater awareness among clinicians and patients, emphasizing strategies such as adequate protein intake, strength training, and emerging pharmacologic options to preserve muscle mass. The discussion underscores the importance of muscle preservation for long-term health and quality of life in individuals using GLP-1 therapies.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Learn from experts in the field of Opioid REMS including appropriate treatment for pain management including opioids, non-opioid analgesics, and non-pharmacological therapies.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode will provide opportunities for the health-system pharmacist to improve understanding of in vivo and viral-based therapies on an institutional level, outline strategies for toxicity prevention and management, and provide recommendations to ensure availability of supportive care therapies to maintain patient safety, when needed. CE for this episode expires 2 years after the date it was originally published.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode addresses the growing challenge of adolescent obesity, which now affects over 22% of US teens. The discussion highlights Food and Drug Administration-approved pharmacotherapy options for adolescents, considerations for side effects and monitoring, and the importance of pairing medications with lifestyle interventions. The episode also explores strategies for providing patient-centered, bias-free care and engaging families in long-term weight management. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Discover the essential contributions of pharmacists in patient care with We’re Your Pharmacist, a monthly podcast from ASHP. This episode features John Wood, Executive Medical Director, Primary Care and Population Health, Penn Medicine Lancaster General Health, and James Kelly, Regional Medical Director and Primary Care Provider, Penn Medicine Lancaster General Health, as they share their perspectives on the vital role pharmacists play in supporting patients. They discuss how pharmacists enhance care, improve outcomes, and strengthen the physician–pharmacist partnership. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Billing opportunities in ambulatory care can often be complicated to navigate, and annual changes in the physician fee schedule can both add opportunities and create confusion. This podcast provides an overview of the 2026 physician fee schedule as it relates to current billing practices, potential new opportunities for pharmacy billing, and other information relevant to ambulatory practice. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode features the 2025 ASHP Best Practice Award winning team at New York Presbyterian Hospital, recognized for their program focusing on ambulatory care pharmacist embedded in clinics improved access to patient care. Listeners will learn how ambulatory care pharmacists created a critical role in promoting equitable, patient-centered care, and how they improved care outcomes among underserved populations. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this podcast, Drs. Joe DiPiro and James Hoffman discuss the ASHP/ASHP Foundation 2026 Pharmacy Forecast Report with host and AJHP Editor in Chief Dr. Daniel Cobaugh.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast explores how the Inflation Reduction Act’s (IRA) drug price negotiation program is reshaping the relationship between CMS, drug manufacturers, and providers. We’ll explore what the proposed IRA implementation framework means for our healthcare system, highlighting the financial, legal, and transparency implications for pharmacies and patients.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode explores the Leader-Member Exchange (LMX) theory, offering pharmacy technicians practical strategies to strengthen relationships with leaders, advocate for their goals, and leverage networking and mentorship to advance their careers.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.